Literature DB >> 3128148

Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis.

E C Lawrence1, K P Brousseau, M B Berger, C C Kurman, L Marcon, D L Nelson.   

Abstract

Sarcoidosis is a granulomatous disorder of unknown cause characterized by activation of T-lymphocytes. We here report the use of an enzyme-linked immunosorbent assay for the soluble interleukin-2 receptor (IL-2R) as a measure of T-cell activation in serum samples and bronchoalveolar lavage fluids in 15 patients with active sarcoidosis. The geometric mean (x divided by SEM) value for soluble IL-2R in serum samples from patients with sarcoidosis was 1,110 (x divided by 1.17) versus 224 (x divided by 1.08) U/ml for normal control subjects (p less than 0.001). Detectable levels of soluble IL-2R were present in bronchoalveolar lavage fluids from 10 of 15 patients with sarcoidosis versus only 2 of 36 normal control subjects (p less than 0.001). Levels of soluble IL-2R in serum samples from untreated patients with sarcoidosis correlated with 67gallium lung scanning scores (p less than 0.05) but not with serum angiotensin-converting enzyme concentrations or constituents of bronchoalveolar lavage. In 5 patients, the level of soluble IL-2R in serum samples fell from 1,499 (x divided by 1.20) to 476 (x divided by 1.58) U/ml (p less than 0.05) after 6 wk of successful treatment with corticosteroids, whereas the changes in soluble IL-2R in bronchoalveolar lavage fluids were more variable. These observations suggest that measurements of soluble IL-2R, particularly in serum samples, may reflect disease activity and be clinically useful in the management of patients with sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128148     DOI: 10.1164/ajrccm/137.4.759

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  25 in total

1.  The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.

Authors:  Saiko Ogata-Suetsugu; Naoki Hamada; Koichi Takayama; Kazuya Tsubouchi; Masako Arimura-Omori; Yoichi Nakanishi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Expression of functional interleukin 2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis.

Authors:  Z Toossi; J R Sedor; J P Lapurga; R J Ondash; J J Ellner
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

4.  Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?

Authors:  R Meliconi; E Lalli; R M Borzì; C Sturani; V Galavotti; G Gunella; R Miniero; A Facchini; G Gasbarrini
Journal:  Thorax       Date:  1990-07       Impact factor: 9.139

5.  Reducing bias during intraocular pressure measurement.

Authors:  J T Gillow; R Aggarwal
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

6.  Orbital lymphoma in systemic sarcoidosis.

Authors:  E Polito; A Leccisotti
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

7.  Subcutaneous sarcoidosis: a clinical analysis of nine patients.

Authors:  Masaru Ando; Eishi Miyazaki; Yutaka Hatano; Suehiro Nishio; Chihiro Torigoe; Mari Yamasue; Yutaka Mukai; Shin-Ichi Nureki; Jun-Ichi Kadota
Journal:  Clin Rheumatol       Date:  2016-07-23       Impact factor: 2.980

8.  IL-2 regulation of soluble IL-2 receptor levels following thermal injury.

Authors:  J A Teodorczyk-Injeyan; B G Sparkes; S Lalani; W J Peters; G B Mills
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

9.  Neurosarcoidosis without systemic sarcoidosis.

Authors:  N Sommer; M Weller; D Petersen; H Wiethölter; J Dichgans
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

10.  Measurement of interleukin-6 in bronchoalveolar lavage fluid by radioimmunoassay: differences between patients with interstitial lung disease and control subjects.

Authors:  K P Jones; S P Reynolds; S J Capper; S Kalinka; J H Edwards; B H Davies
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.